{"id":"slow-tapering-glucocorticoids-inebilizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including opportunistic)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Glucocorticoid-related adverse effects (hyperglycemia, osteoporosis, mood changes)"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":{"chemblId":"CHEMBL2109334","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T17:47:34.515322","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inebilizumab binds to BDCA-2 (blood dendritic cell antigen 2) on plasmacytoid dendritic cells, reducing their activation and type I interferon production, which drives autoimmune disease. The combination with glucocorticoids provides additional immunosuppression through corticosteroid mechanisms (NF-κB inhibition, T cell suppression) while allowing gradual tapering to minimize long-term steroid toxicity.","oneSentence":"Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), combined with slow-tapering glucocorticoids to suppress pathogenic B cell and autoimmune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:07.842Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Autoimmune conditions responsive to B cell and pDC modulation"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT07132398","phase":"PHASE3","title":"Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-01","conditions":"Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Slow-tapering glucocorticoids + Inebilizumab","genericName":"Slow-tapering glucocorticoids + Inebilizumab","companyName":"Tianjin Medical University General Hospital","companyId":"tianjin-medical-university-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), combined with slow-tapering glucocorticoids to suppress pathogenic B cell and autoimmune responses. Used for Systemic lupus erythematosus (SLE), Autoimmune conditions responsive to B cell and pDC modulation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}